Year None2022202120202019201820172016 Date Latest Press Release December 15, 2021 Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients December 1, 2021 Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting November 10, 2021 Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor Conferences November 4, 2021 Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update November 2, 2021 Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15 November 1, 2021 Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV October 21, 2021 Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 Financial Results and Business Update on Thursday, November 4 October 1, 2021 Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) September 21, 2021 Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer September 20, 2021 Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
